SETTING: Despite a steep increase in the number of individuals treated for latent @entity281 (LTBI), few data are available on how treatment is implemented. OBJECTIVE: To obtain baseline information on initiation and completion of treatment for LTBI in Norway in 2009. DESIGN: A descriptive cross-sectional study. RESULTS: All 721 @entity1 treated for LTBI in 2009 in Norway were included, of whom 607 (84%) completed treatment. The treatment regimen generally consisted of 3 months of @entity1215 and @entity3109 . The three main reasons for starting treatment were: 1) countries of origin with high @entity378 ( @entity378 ) prevalence, 2) a positive tuberculin skin test, and 3) a positive interferon gamma release assay. The use of directly observed treatment varied by health region and age. The majority of the 34 medical specialists interviewed saw a need for new national guidelines to improve the selection of high-risk @entity1 with LTBI. CONCLUSIONS: Management of LTBI is in accordance with current guidelines, with a high completion rate. More targeted selection of which @entity1 should be offered preventive treatment is required, and new guidelines and tools to enhance risk assessment are necessary.

Management of latent XXXX in Norway in 2009: a descriptive cross-sectional study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity3109 :: ('MESH:D007538', 'Chemical') :: ['isoniazid'] @entity281 :: ('MESH:D007239', 'Disease') :: ['tuberculous infection'] @entity1215 :: ('MESH:D012293', 'Chemical') :: ['rifampicin'] @entity378 :: ('MESH:D014376', 'Disease') :: ['TB', 'tuberculosis']
@entity281 :: (MESH:D007239,Disease) :: ['tuberculous infection']
